Less than a century ago, Alexander Fleming observed that a mould, Penicillium notatum, inhibited the growth of Staphylococcus bacteria on a petri dish. This discovery paved the way for the development of antibiotics, which
revolutionised medicine in the 20th century.However, the overuse and misuse of antibiotics have led to a growing problem: antimicrobial resistance (AMR). The "golden age" of antibiotics appears to be waning. In the same way that anthelmintic resistance has become a significant challenge in managing parasites in horses, AMR is now a pressing global issue.
The World Health Organization (WHO) has classified AMR as a widespread and serious threat, warning that it "is no longer a prediction for the future; it is happening right now in every region of the world and has the potential to affect anyone, of any age, in any country." While anthelmintic resistance is widely discussed, it is no surprise that bacteria, which reproduce far more rapidly than gastrointestinal parasites, are also developing resistance to substances designed to eliminate them.
In 2016, the Review on Antimicrobial Resistance, commissioned by the UK government and chaired by economist Jim O'Neill, predicted that, if current trends continue, antimicrobial resistance could lead to 10 million deaths annually by 2050, surpassing deaths caused by cancer and other major diseases.
Despite that, public interest in the threat of the downfall of antibiotics appears limited, suggests Bruce Bladon, guest editor of the latest virtual issue of the Equine Veterinary Journal (EVJ). He has chosen 15 of the most pertinent articles on the topic from EVJ and its sister journal, Equine Veterinary Education. His intention is to highlight the significant risk resistance poses and the need to monitor and change equine practice protocols. The virtual collection is free to view here (until 20 January 2025)
Three articles: Antimicrobial use and antimicrobial resistance in horses, Antimicrobial resistance in horses, a call to actionand Room for improvement? The use of antimicrobials in equine respiratory disease present the background on current legislation, use and monitoring of antimicrobials in equine practice.
Audit of antimicrobial use in eleven equine practices over a five-year period (2014–2018) showed an impressive reduction in antibiotic usage but failed to accommodate the fact that the corporatised practices in the study may have been treating less horses. In addition, the withdrawal of a key antimicrobial from sale during the period had reduced antimicrobial usage figures.
Antimicrobial prescribing practice in UK equine veterinary practice and Antimicrobial prescribing and antimicrobial resistance surveillance in equine practice established that potentiated sulphonamides were the most frequently used class of antibiotic in equine practice and that there was a positive adoption of written antimicrobial usage policies. However, both also confirmed that the use of Highest Priority Critically Important Antimicrobials was frequent.
Use of antimicrobials licensed for systemic administration in UK equine practice reported the incidence of antibiotic prescription, to 19.5% (95% CI: 19.2%–19.8%) of 322 equids attended by UK veterinary practices in 2018. Category B antimicrobials were prescribed to 1228 equids (1.9%, 95% CI: 1.8%–2.0%). Active racehorses were 1.6 times more likely to receive antibiotics than non-racehorses.
Antibiotic use in first opinion equine practice in the United Kingdom: Serial point prevalence surveys in 17 practicesShowed that Highest Priority Critically Important Antibiotic usage was similar, at 1.6% of consultations, with potentiated sulphonamides and oxytetracycline constituting two thirds of antibiotic prescriptions.
Antibiotic usage in 14 equine practices over a 10-year period (2012–2021) produced volumetric data compatible with the ESVAC and VARSS methodology. It showed that antibiotic usage did decline during the study period, from 60 to 46 mg/kg. A second metric, the Defined Daily Dose Veterinary per year was also reported, which was 1.52 in 2021, down from 1.7 in 2012.
Changing policy to treat foals with Rhodococcus equi pneumonia in the later course of disease decreases antimicrobial usage without increasing mortality rate reported on the treatment only of foals with larger abscesses. The authors documented a reduction in treatment of foals with rhodococcus pneumonia from 82% to 51% and reduction of median course duration from 41 to 23 days, associated with a statistically insignificant increase in all causes of mortality from 1.15% to 1.65%.
Standing equine cheek tooth extraction: A multivariate analysis of the effect of antibiotics on the risk of post-operative complications reported there was minimal difference in complication rates associated with antibiotic treatment versus extraction
performed without perioperative antimicrobial prophylaxis.
Surgical antimicrobial prophylaxis: Current standards of care reported on the extensive evidence-based guidelines in human surgery, which have been adapted to equine usage.
Post operative synovial sepsis following endoscopic surgery: Increased risk associated with the carpal sheath showed an identical rate of post-operative sepsis following arthroscopy without surgical antimicrobial prophylaxis compared to surgical antimicrobial prophylaxis.
Incidence and risk factors for complications associated with equine general anaesthesia for elective magnetic resonance imaging and Antimicrobial prophylaxis is not indicated for horses undergoing general anaesthesia for elective orthopaedic MRI provided contrasting results. This made it difficult to draw a conclusion about the need for peri-anaesthetic antimicrobials.
“Ultimately, the issue is reducing antimicrobial resistance, particularly in the human healthcare field,” said Bruce Bladon. “It is acknowledged that surgeon behaviour is a limiting factor in the adoption of appropriate surgical antimicrobial prophylaxis policies. Maybe if a clinician was persuaded that avoiding antibiotic prescription would reduce the incidence of antibiotic resistance, they might be more inclined to withhold prophylactic treatment.
“There is a need for a national surveillance programme. If you cannot measure it, you cannot manage it.”
The virtual issue can be found at https://beva.onlinelibrary.wiley.com/doi/toc/10.1001/(ISSN)2042-3306.antibiotics
and will be free to view until 20 January 2025.